IPO

With trillions locked in private startups, Earlyasset emerges from stealth to build the financial 'plumbing' for a more liquid secondary market.

PropW launches a challenge letting traders prove skills in hours, not weeks. But does this fast, low-cost model democratize trading or gamify risk?

With a massive new funding round, Saronic is accelerating its plan to rebuild U.S. shipbuilding with AI-driven autonomous vessels at a WWII-era pace.

Tech advisor Crosslake lands a major new investment from Falfurrias and Leonard Green, signaling a strategic shift in private equity exit strategies.

The neurotech pioneer reports strong sales for its spinal cord injury therapy, secures key FDA approvals, and plans for major US stock market entry.

The digital lender's record revenue and new blockchain platform aim to unlock trillions in illiquid home equity, charting a bold path to profitability.

The robotics firm completed crucial benchtop tests for its novel single-port system, a major step toward clinical use and challenging market leaders.

Sangamo pushes a promising Fabry disease therapy toward the FDA while a cash crunch forces a strategic pivot to brain-targeting neurological cures.

Sound Transit's new Crosslake Connection is a world-first engineering marvel, reshaping travel, tourism, and daily life across the Puget Sound region.

Biotech firm Carbios confirms its landmark recycling plant, appointing a new deputy CEO while battling legal challenges from a former executive.

Facing delisting after a 98% stock plunge, shipping firm Intercont Cayman bets on a reverse split. Is it a lifeline or a delay of the inevitable?

With a landmark NYSE listing and a unique EPA-approved product, CitroTech aims to conquer the fire prevention market. But can it outrun its cash burn?

The biotech firm's oversubscribed funding round will accelerate its universal flu shot and a diverse pipeline targeting cancer, malaria, and Alzheimer's.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

With a $700M war chest and a new veteran president, MISSION Underwriters aims to disrupt Latin America's facultative reinsurance market with its tech platform.

Bowhead Specialty signals a major focus on its tech-driven underwriting, scheduling key events to detail its digital growth engine ahead of its May 5th report.

An ETF offers retail investors a ticket to SpaceX's massive IPO, but a bitter public dispute with critics raises questions about transparency and risk.